EXEL logo
NASDAQ · EXELBiotechnologyUpdated Nov 4, 2026

Exelixis, Inc. ROE

Profitability, historical returns, and peer comparisons.

The ROE as of November 2026 (TTM) for Exelixis, Inc. (EXEL) is 45.54%

According to Exelixis, Inc.’s latest financial reports and current stock price. The company's current ROE is 45.54%. This represents a change of 299.64% compared to the average of 11.40% of the last 4 quarters.

Exelixis, Inc. (EXEL) Historical ROE (quarterly & annually)

How has EXEL ROE performed in the past?

The mean historical ROE of Exelixis, Inc. over the last ten years is 14.05%. The current 45.54% ROE has changed 224.17% with respect to the historical average. Over the past ten years (40 quarters), EXEL's ROE was at its highest in in the December 2016 quarter at 39.32%. The ROE was at its lowest in in the October 2020 quarter at -1.73%.

Quarterly (TTM)
Annual

Average

14.05%

Median

14.75%

Minimum

-78.62%

Maximum

54.12%

Exelixis, Inc. (EXEL) ROE by Quarter and Year

Discovering the peaks and valleys of Exelixis, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 153.10%

Maximum Annual ROE = 54.12%

Minimum Annual Increase = -168.84%

Minimum Annual ROE = -78.62%

Quarterly (TTM)
Annual
YearROEChange
202636.21%55.89%
202523.23%153.10%
20239.18%25.28%
20227.33%-29.92%
202110.45%75.71%
20205.95%-68.76%
201919.04%-64.48%
201853.60%-0.97%
201754.12%-168.84%
2016-78.62%-148.31%

Exelixis, Inc. (EXEL) Average ROE

How has EXEL ROE performed in the past?

The current ROE of Exelixis, Inc. (EXEL) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

22.87%

5-year avg

17.28%

10-year avg

14.05%

Exelixis, Inc. (EXEL) ROE vs. Peers

How is EXEL’s ROE compared to its peers?

Exelixis, Inc.’s ROE is less than Incyte Corporation (7.11%), less than Rigel Pharmaceuticals, Inc. (96.49%), less than HUTCHMED (China) Limited (1.43%), less than Genmab A/S (13.58%), greater than Revolution Medicines, Inc. (-91.93%), greater than Syndax Pharmaceuticals, Inc. (-804.38%), greater than Curis, Inc. (-1035.26%), less than Ipsen S.A. (11.33%), less than Astellas Pharma Inc. (20.41%), less than AstraZeneca PLC (22.31%),

Build a custom stock screener for Exelixis, Inc. (EXEL) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Exelixis, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Exelixis, Inc. (EXEL) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Exelixis, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the ROE?

How can you use the ROE?

What is Exelixis, Inc.'s ROE?

How is the ROE calculated for Exelixis, Inc. (EXEL)?

What is the highest ROE for Exelixis, Inc. (EXEL)?

What is the 3-year average ROE for Exelixis, Inc. (EXEL)?

What is the 5-year average ROE for Exelixis, Inc. (EXEL)?

How does the current ROE for Exelixis, Inc. (EXEL) compare to its historical average?